MetabolicStrong Evidence

Semaglutide

Also known as: Ozempic, Wegovy, Rybelsus, GLP-1 agonist

Weekly GLP-1 receptor agonist, FDA-approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management and other uses.

Evidence

Strong

FDA status

FDA-approved

Source

Synthetic GLP-1 receptor agonist

Overview

Weekly GLP-1 receptor agonist, FDA-approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management and other uses.

Mechanism of Action

Binds GLP-1 receptors in pancreas and brain, increases insulin secretion and decreases glucagon, slows gastric emptying for prolonged satiety, acts on hypothalamic appetite centers to reduce food intake, 94% homology to native GLP-1 with modifications for extended half-life (7 days).

What research has looked at

Effects reported in studies, not proven benefits. See the evidence section below for how strong the research is.

  • Weight loss (STEP trials)
  • Improved glycemic control in diabetes
  • Reduced appetite and cravings
  • Lower risk of heart attack, stroke and cardiovascular death in adults with heart disease and obesity or overweight (Wegovy)
  • Lower HbA1c
  • Slower kidney disease worsening in type 2 diabetes with chronic kidney disease (Ozempic)

Researched for

Includes FDA-approved uses where marked; other items are research topics, not approved uses.

Type 2 diabetesObesity (BMI ≥30 or ≥27 with comorbidities)Metabolic syndromeMASH with moderate-to-advanced liver scarring (Wegovy, accelerated approval)Weight management

How Gabriel approaches peptides

Semaglutide can be requested through Gabriel. A licensed clinician at a telehealth partner reviews your request and decides whether it's appropriate. Gabriel never gives peptide dosing.

Compounded medications aren't FDA-approved. A licensed clinician decides what's right for you.

How to get semaglutide online

Read the peptide therapy guide

Research & Evidence

Evidence Level
Strong
Studies

Multiple large RCTs (STEP, SUSTAIN trials), FDA approved

Summary

Large randomized trials (STEP, SUSTAIN, SELECT, FLOW, ESSENCE) support its FDA-approved uses: type 2 diabetes, chronic weight management, lowering cardiovascular risk in adults with heart disease and obesity or overweight (2024), kidney disease in type 2 diabetes (2025) and MASH with moderate-to-advanced fibrosis (accelerated approval, 2025).

Safety Information

Potential Side Effects

  • •Nausea
  • •Vomiting
  • •Diarrhea
  • •Constipation
  • •Abdominal pain
  • •Risk of pancreatitis
  • •Gallbladder disease

Contraindications

  • Medullary thyroid carcinoma history
  • MEN 2 syndrome
  • Pregnancy
  • Breastfeeding
  • Pancreatitis history

Interactions

  • ⚠Delays gastric emptying (affects oral medication absorption)
  • ⚠May potentiate insulin/sulfonylureas

Quick Facts

CategoryMetabolic
SourceSynthetic GLP-1 receptor agonist
StatusFDA-approved (Ozempic, Rybelsus, Wegovy). Compounded semaglutide is not FDA-approved.